OncologyEducation presents MedOncNow podkast

Targeting HER2 Alterations in NSCLC with Dr. Barbara Melosky

0:00
33:51
Do tyłu o 15 sekund
Do przodu o 15 sekund

In this episode, Dr. Barb Melosky takes us through practical aspects of using HER2 targeted agents in HER2 altered advanced NSCLC.  This is particularly timely given we now have access through company sponsored SAP programs for both Zongertinib and Sevabertinib. 

 

Więcej odcinków z kanału "OncologyEducation presents MedOncNow"